Search clinical trials for: Immune Globulin Intravenous (Human), 10%

Total 1143 results

Baxalta now part of Shire

Completed

Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously

Primary Immunodeficiency Diseases (PID)

United States
Baxalta now part of Shire

Completed

Phase 2/3 Study of IGSC, 20% in PIDD

Primary Immunodeficiency Diseases (PID)

United States, Canada
Baxalta now part of Shire

Terminated

Phase 3 IGIV, 10% in Alzheimer´s Disease

Alzheimer´s Disease

United States, Poland, United Kingdom, Belgium, Spain, Japan, Canada, Australia
Baxalta now part of Shire

Completed

Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects

Primary Immunodeficiency Diseases (PID)

United States
National Institute of Allergy and Infectious Diseases...

Terminated

Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%

Kidney Failure, Chronic

United States
Baxalta now part of Shire

Completed

Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD

Primary Immunodeficiency Diseases (PID)

United States
Biotest Pharmaceuticals Corporation

Completed

Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.

Liver Cirrhosis | Hepatitis, Viral, Human | Hepatocellular Carcinoma | Hepatitis C Infection | Viruses

United States
Green Cross Corporation
Atlantic Research Group

Recruiting

Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency

Primary Immune Deficiency

United States
ADMA Biologics, Inc.

Completed

Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)

Primary Immune Deficiency Disorders (PIDD)

United States
Baxalta now part of Shire

Completed

Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders

Primary Immunodeficiency Diseases (PID) | Immune Thrombocytopenic Purpura (ITP) | Kawasaki Syndrome

United States
University of Chicago
Sunnybrook Health Sciences Centre; University of British Columbia; University... and other collaborators

Completed

Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage

Abortion, Habitual | Miscarriage, Recurrent

United States
Baxalta now part of Shire
Alzheimer's Disease Cooperative Study (ADCS)

Completed

A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease

Alzheimer´s Disease

United States, Canada
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult Participants

Healthy Volunteers

United States
Inova Health Care Services
CSL Behring

Withdrawn

IVIG in Acute Ischemic Stroke: A Pilot Study (IVIG/AIS)

Ischemic Stroke

United States
Baxalta now part of Shire

Terminated

Long-Term Study of IGIV, 10% in Alzheimer´s Disease

Alzheimer´s Disease

United States
Grifols Therapeutics LLC

Completed

Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients

Common Variable Immunodeficiency | Severe Combined Immunodeficiency | Wiskott-Aldrich Syndrome | Agammaglobulinemia | Immunologic Deficiency Syndrome

Canada, United States
Green Cross Corporation
Parexel; Atlantic Research Group

Completed

Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency

Immunologic Deficiency Syndromes

Canada, United States
Biotest
Syneos Health

Completed

Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID

Primary Immunodeficiency Disease

United States, Germany, Hungary, Russian Federation, Spain
Green Cross Corporation
Atlantic Research Group

Completed

Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency

Immunologic Deficiency Syndrome

United States, Canada
Prometic Biotherapeutics, Inc.
Atlantic Research Group

Completed

Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%

Primary Immunodeficiency

United States
Baxalta now part of Shire

Completed

Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy

Multifocal Motor Neuropathy

United States, Canada, Denmark
Baxalta now part of Shire

Completed

Immune Globulin Subcutaenous (Human), 20%

Primary Immunodeficiency Diseases (PID)

Germany, Austria, Hungary, Sweden, United Kingdom
Baxalta now part of Shire

Completed

Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura

Immune Thrombocytopenic Purpura (ITP)

Poland, Hungary, Germany, Czechia
University of Tennessee

Completed

Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction

Multiple Myeloma | Plasma Cell Neoplasm

United States
Takeda
Takeda Development Center Americas, Inc.

Recruiting

A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

Primary Immunodeficiency Diseases (PID)

United States
University of South Florida
CSL Behring

Completed

Subcutaneous Immunoglobulin for CIDP (SCIG)

Chronic Inflammatory Demyelinating Polyneuropathy

United States
National Institute of Allergy and Infectious Diseases...

Withdrawn

Vaccinia Immune Globulin in Treating or Preventing Vaccinal Infection

Communicable Diseases | Healthy
Baxalta now part of Shire

Completed

A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)

Primary Immunodeficiency Diseases (PID)

Japan
Queen Saovabha Memorial Institute

Completed

Human Rabies Immunoglobulin (HRIG)- Dosage Determination and Interference With the Active Immune Response

Rabies

Thailand
Grifols Therapeutics LLC

Completed

Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP

Purpura, Thrombocytopenic, Idiopathic

United States
Baxalta now part of Shire
Takeda Development Center Americas, Inc.

Completed

A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

United States, Israel, Canada, Spain, Czechia, Croatia, Poland, Italy, Serbia, Germany, Argentina, Mexico, Turkey, United Kingdom, Brazil, France, Greece, Slovakia, Colombia, Denmark, Norway, Sweden
Grifols Therapeutics LLC

Completed

Anti-Hepatitis A Virus, Pharmacokinetics, and Safety of Immune Globulin (Human) (GamaSTAN)

Anti-Hepatitis A Antibody Levels in Heathy Subjects

United States
Baxalta now part of Shire

Completed

Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)

Primary Immunodeficiency Diseases (PID) | Hypogammaglobulinemia | Agammaglobulinemia

Finland, Sweden
Daping Hospital and the Research Institute of Surgery...

Recruiting

Intravenous Immunoglobin Transfusion in Preterm Infants With Encephalopathy of Prematurity

Preterm Infants

China
Vera Bril

Unknown

Panzyga in CIDP Administered at Different Infusion Rates (Panzyga-CIDP)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Canada
Emergent BioSolutions
Centers for Disease Control and Prevention

Enrolling by invitation

VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia Infection

Complication of Smallpox Vaccination
Grifols Therapeutics LLC

Completed

Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency

Primary Immunodeficiency

United States, Canada
Nabi Biopharmaceuticals

Completed

Safety and Behavior of S. Aureus Immune Globulin Intravenous(Human), [Altastaph] in Patients With S. Aureus Bacteremia and Continuing Fever

Staphylococcal Infections
CSL Behring

Completed

Follow-up Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)

Primary Immune Deficiency Disorder

Japan
Baxalta now part of Shire

Completed

Gammagard Liquid and rHuPH20 in PID

Primary Immunodeficiency Diseases (PID)

United States, Canada
FFF Enterprises
OMRIX Biopharmaceuticals

Completed

A Clinical Study of Intravenous Immunoglobulin (IGIV)

Immunologic Deficiency Syndromes

United States, Canada
CSL Behring

Completed

Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study)

Primary Immune Deficiency

Japan
Nabi Biopharmaceuticals

Completed

Safety Study of an Intravenous Staphylococcus Aureus Immune Globulin (Human), [Altastaph] in Low-Birth-Weight-Neonates

Staphylococcal Infections
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia

Exposure During Pregnancy

Poland, Czechia, United States, Germany, Slovakia
Octapharma

Terminated

Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency Diseases

Immunologic Deficiency Syndromes

Austria
The Methodist Hospital Research Institute
Grifols Biologicals, LLC

Recruiting

Survey of Human Rabies Immune Globulin Safety in Children

Rabies | Rabies Human | Pediatrics | Rabies Virus Infection

United States
Mazen Dimachkie, MD
CSL Behring

Completed

Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis

Myasthenia Gravis

United States, Canada
Synermore Biologics Co., Ltd.
inVentiv Health Clinical

Completed

A Comparison of the Safety, PD and PK of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines (RabiesMab)

Human Rabies

United States
ADMA Biologics, Inc.

Terminated

Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation

Transplantation Infection | Evidence of Liver Transplantation | Sequelae of Viral Hepatitis

United States
Grifols Therapeutics LLC

Completed

Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency

Primary Immunodeficiency

Spain, France, Germany, United Kingdom, Australia, Czechia, Hungary, Poland, Sweden

Search clinical trials for: Immune Globulin Intravenous (Human), 10%

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations